A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-14 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
In 1886, Eugen Goldstein discovered canal rays (also known as anode rays) exiting from perforations in the discharge tube. Wilhelm Wien in 1898 showed that these rays had a charge opposite to the negative electrons discovered by J. J. Thomson, but with a much higher mass to charge ratio. Later that year Thomson was able to determine a value for the magnitude of the electric charge, e, and show that the canal rays included material with charge-to-mass ratio (q/m) consistent with the hydrogen ion. Following the discovery of the atomic nucleus by Ernest Rutherford in 1913, Antonius van den Broek proposed that the place of each element in the periodic table (its atomic number) is equal to its nuclear charge. Van den Broek speculated that the nucleus contained alpha particles with four positive charges and two electrons, the first version of the nuclear-electron hypothesis. (The modern model of two positive protons and two neutrons would take many years to discover). Also in 1913 Niels Bohr presented a theory of atomic structure which predicted electronic transitions related to nuclear charge. This was confirmed experimentally by Henry Moseley in 1913 when he showed that the energy of X-ray spectra lines of many elements followed a pattern based on atomic number. In 1919, after a long series of sporadic experiments interrupted by WWI, Rutherford discovered what he called artificial disintegration of nitrogen atoms.
1979 Elected member, European Molecular Biology Organization. 1987 Meyenburg Prize for Cancer Research. 1995 Elected member, Academia Europaea. 1997 Doctorate honoris causa, Pomeranian Medical Academy, Szczecin, Poland. 1998 Carl Zeiss Prize, German Society of Cell Biology, (shared with Klaus Weber). 1998 Helena Rubenstein / UNESCO Prize for Women in Science (UK). 2002 L'Oréal / UNESCO Prize for Women in Science. 2003-2006 President of the International Union of Biochemistry and Molecular Biology (IUBMB). 2005 Outstanding Science Alumni Award, Pennsylvania State University, USA. 2014. Federal Cross of Merit, 1st Class, Federal Republic of Germany. 2007 Dorothea Schlözer Medal, University of Göttingen, Germany.
=== Other uses === PVDF is used for specialty monofilament fishing lines, sold as fluorocarbon replacements for nylon monofilament. The surface is harder, so it is more resistant to abrasion and sharp fish teeth. Its refractive index is lower than nylon, which makes the line less discernible to fish eyes. It is also denser than nylon, making it sink faster towards fish. PVDF is used for specialty roofing coatings to improve UV resistance and increase roof color retention.
Through various studies in which functional derivatives of ribosomes were mixed with puromycin (an analog of the 3' end of an aa-tRNA) it was determined that adding LepA to a post transcriptionally modified ribosome prevents dipeptide formation as it inhibits the binding of aa-tRNA to the A site.
Sources: en.wikipedia.org
"Molecular mechanisms of insulin resistance and associated diseases". Clinica Chimica Acta. 375 (1–2): 20–35. doi:10.1016/j.cca.2006.07.005. PMID 16956601. Tomazic, J; Karner, P; Vidmar, L; Maticic, M; Sharma, PM; Janez, A (2005). "Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART". Acta Dermatovenerologica Alpina, Pannonica et Adriatica. 14 (3): 99–105. PMID 16200335. Tomažič, Janez; Silič, Anja; Karner, Primož; Vidmar, Ludvik; Matičič, Mojca; Poljak, Mario; Ihan, Alojz; Janež, Andrej (2004). "Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients". Wiener Klinische Wochenschrift. 116 (21–22): 755–9. doi:10.1007/s00508-004-0268-9. PMID 15628647. S2CID 24715784. Tomazic, M.; Janez, A.; Sketelj, A.; Kocijancic, A.; Eckel, J.; Sharma, P. (2002). "Comparison of alterations in insulin signalling pathway in adipocytes from type II diabetic pregnant women and women with gestational diabetes mellitus". Diabetologia. 45 (4): 502–8. doi:10.1007/s00125-002-0791-z. PMID 12032625. (Retracted) Hevener, A.; Reichart, D.; Janez, A.; Olefsky, J. (2002). "Female Rats Do Not Exhibit Free Fatty Acid-Induced Insulin Resistance". Diabetes. 51 (6): 1907–12. doi:10.2337/diabetes.51.6.1907. PMID 12031980. Hevener, A. L.; Reichart, D.; Janez, A.; Olefsky, J. (2001). "Thiazolidinedione Treatment Prevents Free Fatty Acid-Induced Insulin Resistance in Male Wistar Rats". Diabetes. 50 (10): 2316–22. doi:10.2337/diabetes.50.10.2316. PMID 11574414. Ravnik-Oblak, M; Janez, A; Kocijanicic, A (2001).
In April 2021, Bukele inaugurated a vaccination center at Hospital El Salvador to administer up to 10,000 doses of the COVID-19 vaccine per day; the center closed in August 2022, as dose administrations diminished. Most of El Salvador's COVID-19 vaccines were donated by the United States and China. On 13 May 2021, Bukele donated 34,000 doses of the COVID-19 vaccine to seven towns in Honduras after pleas from their mayors for vaccine doses. El Salvador had received 1.9 million doses at the time, and Honduras had only received 59,000. Gabriel Labrador, a journalist for El Faro, told El País that Bukele made the donation to Honduras to improve his public image in Central America.
Nonproliferation. Preventing the spread of materials, technology, and expertise related to weapons of mass destruction (WMD) and detecting WMD proliferation activities worldwide. Domestic security: Anticipating, innovating and delivering technological solutions to prevent and mitigate devastating high-leverage attacks on U.S. soil. Defense: Developing and demonstrating new concepts and capabilities to help the Department of Defense prevent and deter harm to the nation, its citizens and its military forces. Intelligence: Working at the intersection of science, technology, and analysis to provide insight into the threats to national security posed by foreign entities. Energy and environmental security: Furnishing scientific understanding and technological expertise to devise energy and environmental solutions at global, regional and local scales.
Sources: en.wikipedia.org
Barnsley won the 2006 League One play-off final and remained in the Championship for eight seasons. Relegated in 2014, they won both the 2016 Football League Trophy final and the 2016 League One play-off final, though this time spent just two seasons in the Championship. In 2017, a majority stake in the club was sold to a consortium that included Chien Lee, Neerav Parekh and Billy Beane. Barnsley won promotion from League One with a second-place finish in the year 2019, before being relegated out of the Championship again in the year of 2022. Barnsley have spent more seasons and played more games at the second level of English football than any other team. The club's main rivals are fellow Yorkshire clubs Sheffield Wednesday, Sheffield United, Leeds United, Huddersfield Town and Rotherham United.
=== Development === Insecticides with systemic activity against sucking pests, which are safe to pollinators, are sought after, particularly in view of the partial bans on neonicotinoids. Revised 2023 guidance by registration authorities describes the bee testing that is required for new insecticides to be approved for commercial use.
Salernitana originally wore light blue and white striped shirts, known in Italy as biancocelesti. The blue on the shirt was chosen to represent the sea, as Salerno lies right next to the Gulf of Salerno and has a long tradition as a port city. In the 1940s, the club changed to garnet coloured shirts, which has gained them the nickname granata in their homeland. During the 2011–12 season their kit colours were striped blue and deep red, resembling F.C. Barcelona. The symbol of St. Matthew, patron saint of Salerno, was also a part of the redesigned kit. Since renaming the club US Salernitana 1919, however, their home colours have again been the traditional garnet. The 100th anniversary logo was announced on 24 June 2019, and appeared on their 2019–20 season kits.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.